Eledon Pharmaceuticals (FRA:2TK) Total Liabilities : €56.60 Mil (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Eledon Pharmaceuticals Total Liabilities?

Eledon Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2024 was €56.60 Mil.

Eledon Pharmaceuticals's quarterly Total Liabilities declined from Jun. 2024 (€119.83 Mil) to Sep. 2024 (€34.71 Mil) but then increased from Sep. 2024 (€34.71 Mil) to Dec. 2024 (€56.60 Mil).

Eledon Pharmaceuticals's annual Total Liabilities increased from Dec. 2022 (€8.13 Mil) to Dec. 2023 (€75.06 Mil) but then declined from Dec. 2023 (€75.06 Mil) to Dec. 2024 (€56.60 Mil).

Eledon Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Eledon Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eledon Pharmaceuticals Total Liabilities Chart

Eledon Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

5.42

5.80

8.13

75.06

56.60

Eledon Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															75.06	5.52	119.83	34.71	56.60

Eledon Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Eledon Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	11.056	+	(0.611	+	42.846
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	2.085	+	0	+	0)
	=	56.60

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	169.422	-	112.824
	=	56.60

Eledon Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	11.056	+	(0.611	+	42.846
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	2.085	+	0	+	0)
	=	56.60

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	169.422	-	112.824
	=	56.60

Eledon Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Eledon Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Eledon Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eledon Pharmaceuticals Inc (FRA:2TK) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ELDN:USA 2TK:Germany

Address

19800 MacArthur Boulevard, Suite 250, Irvine, CA, USA, 92612

Website

https://www.eledon.com

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Eledon Pharmaceuticals Headlines

No Headlines